JPMorgan Chase & Co. set a €104.00 ($120.93) price target on Merck KGaA (FRA:MRK) in a research report report published on Friday morning, Borsen Zeitung reports. The brokerage currently has a neutral rating on the healthcare company’s stock.
MRK has been the topic of a number of other reports. UBS Group set a €104.00 ($120.93) price objective on shares of Merck KGaA and gave the company a neutral rating in a research note on Tuesday, November 26th. DZ Bank reaffirmed a buy rating on shares of Merck KGaA in a report on Friday, November 22nd. Bank of America set a €110.00 ($127.91) target price on shares of Merck KGaA and gave the company a neutral rating in a research report on Friday, September 13th. Independent Research set a €103.00 ($119.77) price target on Merck KGaA and gave the company a neutral rating in a research note on Thursday, September 19th. Finally, Barclays set a €85.00 ($98.84) price target on Merck KGaA and gave the stock a sell rating in a research report on Monday, November 18th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and three have given a buy rating to the stock. Merck KGaA presently has an average rating of Hold and a consensus price target of €103.07 ($119.84).
Shares of MRK traded up €0.35 ($0.41) on Friday, reaching €104.35 ($121.34). 341,983 shares of the company’s stock were exchanged. The business has a 50 day moving average price of €106.82 and a two-hundred day moving average price of €98.03. Merck KGaA has a 12 month low of €76.60 ($89.07) and a 12 month high of €115.00 ($133.72).
Merck KGaA Company Profile
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Recommended Story: What does a bar chart display?
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.